Practical considerations for optimal transdermal drug delivery

American Journal of Health-System Pharmacy

Volumn 69, Issue 2, 2012, Pages 116-124

  Durand, Cheryl ^a   Alhammad, Abdullah ^a   Willett, Kristine C ^a  

^a Massachusetts College of Pharmacy and Health Sciences Manchester   (United States)

Author keywords

Adhesion; Drug administration; Drug administration routes; Industry, pharmaceutical; Patches transdermal; Patient information; Technology; Toxicity

Indexed keywords

CLONIDINE; SCOPOLAMINE;

DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG PACKAGING; DRUG SAFETY; ELECTRIC CONDUCTIVITY; ELECTROPORATION; HEAT; HUMAN; INTERMETHOD COMPARISON; IONTOPHORESIS; LIPOPHILICITY; MOLECULAR WEIGHT; PATIENT COMPLIANCE; PATIENT COUNSELING; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN PENETRATION; STRATUM CORNEUM; SUN EXPOSURE; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH; TREATMENT DURATION; UNITED STATES; WASTE DISPOSAL;

EID: 84856297564     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110158     Document Type: Review

References (57)

1. Scheindlin S. Transdermal drug delivery: past, present, future. Mol Interv. 2004; 4:308-12. (Pubitemid 40124375)
2. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res Technol. 2008; 14:249-60.
3. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009; 26:920-35.
4. Hong I, Gabay M, Ladolce A. Safety concerns involving transdermal patches and magnetic resonance imaging (MRI). Hosp Pharm. 2010; 45:771-8.
5. Padula C, Nicoli S, Aversa V et al. Bioadhesive film for dermal and transdermal drug delivery. Eur J Dermatol. 2007; 17:309-12. (Pubitemid 47051545)
6. Subedi RK, Oh SY, Chun MK et al. Recent advances in transdermal drug delivery. Arch Pharm Res. 2010; 33:339-51.
7. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008; 26:1261-8.
8. Wokovich AM, Prodduturi S, Doub WH et al. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm. 2006; 64:1-8. (Pubitemid 44150598)
9. Arora A, Kisak E, Karande P et al. Multicomponent chemical enhancer formulations for transdermal drug delivery: more is not always better. J Control Release. 2010; 144:175-80.
10. Ball AM, Smith KM. Optimizing transdermal drug therapy. Am J Health-Syst Pharm. 2008; 65:1337-46.
11. Zuppa AF, Tejani SM, Cullen EJ. Plasma concentrations following application of whole versus cut transdermal clonidine patches to critically ill children. J Pediatr Pharmacol Ther. 2004; 91:43-8.
12. Wong NN, Chen JL, Luks-Golger D. Absorption of clonidine from a halved transdermal system - a pilot system. J Pharm Technol. 2001; 17:84-9. (Pubitemid 32476734)
13. Butrans (buprenorphine) transdermal system package insert. Stamford, CT: Purdue Pharma L.P.; 2010 Aug.
14. Qutenza (capsaicin) package insert. San Mateo, CA: NeurogesX, Inc.; 2011 Nov.
15. Catapres-TTS (clonidine) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009 Nov.
16. Clonidine patch package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2010 Jul.
17. Clonidine patch package insert. Spring Valley, NY: Par Pharmaceutical, Inc.; 2009 Feb.
18. Clonidine transdermal system package insert. Grand Rapids, MI: Teva Pharmaceuticals; 2010 May.
19. Flector (diclofenac epolamine topical patch) package insert. Bristol, TN: King Pharmaceuticals; 2009 Oct.
20. Alora (estradiol transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2005 May.
21. Climara (estradiol transdermal system) package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2007 Dec.
22. Estraderm (estradiol transdermal system) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004 Jun.
23. Menostar (estradiol transdermal system) package insert. Wayne, NJ: Bayer Health-Care Pharmaceuticals Inc.; 2007 Mar.
24. Vivelle-Dot (estradiol transdermal system) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004 Jun.
25. Estradiol transdermal system package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2008 Aug.
26. Climara Pro (estradiol/levonorgestrel transdermal system). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2007 May.
27. CombiPatch (estradiol/norethindrone transdermal system) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005 Nov.
28. Duragesic (fentanyl transdermal system) package insert. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008 Feb.
29. Fentanyl transdermal system package insert. Weston, FL: Apotex Corp.; 2010 Dec.
30. Fentanyl transdermal system package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2009 Dec.
31. Fentanyl transdermal system package insert. Broomfield, CO: Sandoz Inc.; 2009 Jul.
32. Fentanyl transdermal system package insert. Sellersville, PA: Teva Pharmaceuticals; 2009 Jan.
33. Fentanyl transdermal system package insert. Corona, CA: Watson Laboratories, Inc.; 2008 Aug.
34. Sancuso (granisetron transdermal system) package insert. Bedminster, NJ: ProStrakan Inc.; 2008 Sep.
35. Lidoderm (lidocaine) package insert. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010 Feb.
36. Synera (lidocaine/tetracaine) package insert. Salt Lake City, UT: Zars Pharma, Inc.; 2010 May.
37. Daytrana (methylphenidate transdermal system) package insert. Miami, FL: Noven Pharmaceuticals, Inc.; 2010 Nov.
38. Nicoderm CQ (nicotine patch) product information. Research Triangle Park, NC: GlaxoSmithKline Consumer Healthcare, L.P.; 2007 Apr.
39. Nicotine transdermal system product information. Parsipanny, NJ: Novartis Consumer Health, Inc.; 2010 Jan.
40. Minitran (nitroglycerin transdermal system) product information. Bristol, TN: Graceway Pharmaceuticals, LLC; 2006 Jan.
41. Nitro-Dur (nitroglycerin transdermal system) product information. Kenilworth, NJ: Key Pharmaceuticals, Inc.; 2004 Dec.
42. Nitroglycerin transdermal system package insert. Emigsville, PA: Hercon Laboratories Corporation; 2008 Mar.
43. Nitroglycerin transdermal system package insert. Mequon, WI: Kremers Urban, LLC; 2007 Oct.
44. Nitroglycerin transdermal system package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2008 Oct.
45. Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2010 Apr.
46. Oxytrol (oxybutynin transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2006 May.
47. Exelon (revastigmine transdermal system) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010 Aug.
48. Neupro (rotigotine transdermal system) product information. Mequon, WI: Schwaz Pharma, LLC; 2006 Jun.
49. Cada DJ, Levien T, Baker DE. Rotigotine transdermal system. Hosp Pharm. 2007; 42:939-50.
50. Transderm Scop (scopolamine transdermal system) package insert. Mountain View, CA: Alza Corporation; 2006 Mar.
51. Emsam (selegiline transdermal system) package insert. Tampa, FL: Somerset Pharmaceuticals, Inc.; 2010 Jan.
52. Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2005 Nov.
53. Kanal E, Barkovich AJ, Bell C et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007; 188:1447-74. (Pubitemid 46866845)
54. Center for Drug Evaluation and Research, Food and Drug Administration. Risk of burns during MRI scans from transdermal drug patches with metallic backings. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ PublicHealthAdvisories/ucm111313.htm (accessed 2011 Jun 5).
55. Aluminum-containing transdermal patches: a risk of burns. Prescrire Int. 2007; 16:246.
56. Teske J, Weller JP, Larsch K. Fatal outcome in a child after ingestion of a transdermal fentanyl patch. Int J Legal Med. 2007; 121:147-51. (Pubitemid 46233196)
57. Woolf A, Burkhart K, Caraccio T et al. Childhood poisoning involving transdermal nicotine patches. Pediatrics. 1997; 99:E4.